Promising bone-related therapeutic targets for rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Promising bone-related therapeutic targets for rheumatoid arthritis.

Promising bone-related therapeutic targets for rheumatoid arthritis.

http://www.wikidata.org/entity/Q33554023

about

Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.Human Dickkopf-1 (huDKK1) protein: characterization of glycosylation and determination of disulfide linkages in the two cysteine-rich domains.A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.Bone formation and resorption are both increased in experimental autoimmune arthritis.Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion.Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis.Inhibition of inflammatory arthritis using fullerene nanomaterials.Therapeutic targets for bone metastases in breast cancer.Bone Targeted Therapies for Bone Metastasis in Breast Cancer Association between arthritis score at the onset of the disease and long-term locomotor outcome in adjuvant-induced arthritis in rats Wnt signaling and injury repair.The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5 Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 β -induced RANKL, OPG, TNF α , and IL-6 expression in human rheumatoid synoviocyte MH7A.Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development.CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.TNF and Bone Remodeling.The Impacts of Chrysanthemum indicum Extract on Oxidative Stress and Inflammatory Responses in Adjuvant-Induced Arthritic Rats.Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis.Vaccination with DKK1-derived peptides promotes bone formation and bone mass in an aged mouse osteoporosis model.Recombinant human endostatin inhibits TNF-alpha-induced receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes in mice with adjuvant arthritis.Interleukin-29 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via MAPK signaling pathways.Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.

P2860

Q26750589-5B36A42E-2994-4E92-A372-2AD1F81615C7 Q27006383-4BB53AE4-A698-4618-91A7-0B9EFC577C5B Q30497635-EDAE01E8-BDB4-4DEC-9786-B953FE4AA71B Q31021577-D6235526-0D90-4022-A683-F12288967CFC Q33976893-1AC0459B-A739-4097-9906-246E335C8B1A Q34148305-B9AB3DBD-7515-4ACC-A1EE-C1972CE257DB Q34541587-179A3006-7B53-4033-A63E-6B486A2B8820 Q34974033-57234C3A-83CA-4412-A02E-4D01ECAEE4AB Q35060214-A07339C7-BFE8-4B55-8CCA-9DA75A50EE2F Q35238090-D02B62B4-7378-431A-9AFE-45007738EDFC Q35287485-BFAD3B11-28E1-4769-8E6D-108355C54C0C Q35448218-6B8F8087-7223-4E87-9B32-90334ADDFB0D Q35558919-1904D112-BF65-4F43-B7F7-B1004F4CAE2D Q35750448-223BA797-239D-4BA2-B978-F361D1AE0772 Q35863335-9FFA8631-0EC2-4109-8603-84695917D6C4 Q36119516-654A3285-EBDD-4BF2-912A-CA213DD6D632 Q36286414-1CD6F02D-9E6A-40F0-8050-1D08149C1833 Q36568516-49730464-B23D-477A-9455-7BE2EB976F91 Q36603276-5D29D877-E702-4D2C-B36C-5C8518F2D183 Q37195704-903EB2C6-5E79-4C13-AFBB-70E9FF1B8EE4 Q37375129-7972AE35-89A2-4CCB-8BA5-F1373D8C7E9F Q37813237-8FC8C205-6DE2-4156-BFB9-A102CD723307 Q38218977-B8175E76-9EE5-4A98-B007-9C659D855FD9 Q38685181-888CBD21-4FDD-46DB-9692-57ACC464E3F0 Q39185214-0DDB76ED-400E-4D99-AA92-6B3AD7B185B6 Q39287117-6BDC99BF-A294-4D75-9251-1D6D4D7B6302 Q40218213-BD2268C6-35C4-44E2-86B8-B5D971525129 Q42165286-AF8E8106-F61F-4566-A8C0-7B6D906D6E07 Q42568723-148822DA-E4DE-410A-9F37-3A32B5DC04E3 Q51135494-7A5259E0-0F31-4513-AF7B-50C431868B01 Q51404270-6D18BED8-05E4-4D7F-98D4-A885A3631F3E Q53327148-68636CCD-453B-4793-B6B0-47FE0B6CB051 Q53793555-7A1BD15A-5E5A-48A7-A7A5-B98106560955

P2860

Promising bone-related therapeutic targets for rheumatoid arthritis.

http://www.wikidata.org/entity/Q33554023

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Promising bone-related therapeutic targets for rheumatoid arthritis.

@ast

Promising bone-related therapeutic targets for rheumatoid arthritis.

@en

Promising bone-related therapeutic targets for rheumatoid arthritis.

@nl

type

label

Promising bone-related therapeutic targets for rheumatoid arthritis.

@ast

Promising bone-related therapeutic targets for rheumatoid arthritis.

@en

Promising bone-related therapeutic targets for rheumatoid arthritis.

@nl

prefLabel

Promising bone-related therapeutic targets for rheumatoid arthritis.

@ast

Promising bone-related therapeutic targets for rheumatoid arthritis.

@en

Promising bone-related therapeutic targets for rheumatoid arthritis.

@nl

P1433

Q33554023-14A3579B-0384-4F68-8932-7186F79FE75D

P1476

Q33554023-A12453B9-D022-43CA-AE89-C9763CE81E07

P2093

Q33554023-50A91882-3979-4633-912E-EFB094B16EF0

Q33554023-E317B761-812A-44EE-B1FB-437BDF013304

P2860

Q33554023-060FEB5E-B45A-45A3-899A-4B2A312295FD

Q33554023-0995234C-226E-4D8F-AC72-97438CAF9FDC

Q33554023-112408EE-D814-43C8-8E76-F69D4AD0B8A4

Q33554023-14BFEE0D-224D-40C6-91C6-CBA0F41F5AB5

Q33554023-1B2A587E-A739-4BDA-9288-FCA3AE0E64F5

Q33554023-1B7C67FC-8E28-4A60-97AD-32288855C8BC

Q33554023-1BAF2E07-49F9-4B14-9529-0A881F7D1AAA

Q33554023-1CDA3F3B-1994-4D2D-874F-1112057CCACD

Q33554023-1FDE1A85-EAA2-4444-8266-7445F33FEB53

Q33554023-2FF6CFB8-69B3-4CAD-B476-C9D296944C56

P2888

Q33554023-61CDABF3-4268-4A92-8292-4799166594FC

P304

Q33554023-E76C968B-0B13-4263-84DF-1C34BA5C5941

P31

Q33554023-8CD535A9-DAF8-44C6-A990-BB7D4F425787

P356

Q33554023-7842AE06-0B9D-4187-9CF8-8303DD1653B1

P407

Q33554023-781841C0-230E-4E13-87E2-73BCC8342431

P433

Q33554023-22D3F430-B184-4AAE-942B-D9CC749935E7

P478

Q33554023-6AC29D33-14FC-4CC0-917B-5B71FFC43C85

P50

Q33554023-A8275379-7FA8-4DFF-A462-3F65D2EA71A9

P577

Q33554023-AD2CBE58-3C99-409C-A821-0F40A57B666F

P5875

Q33554023-BB35B463-4902-485F-99D6-AB2DDA4A6249

P6179

Q33554023-A0DC8FF1-2CCE-4AC6-AA7E-D12FB9FB3177

P698

Q33554023-41F2F3CC-EC8D-453E-A3ED-32494A308C4B

P932

Q33554023-B1660B25-9751-4786-9CF8-EDD4C8651078

P356

NRRHEUM.2009.175

P1433

Nature Reviews Rheumatology

P1476

Promising bone-related therapeutic targets for rheumatoid arthritis.

@en

P2093

Michael J Townsend

http://www.w3.org/2001/XMLSchema#string

Yongwon Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow

CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis

Skeletal remodeling in health and disease

Denosumab: anti-RANKL antibody

P2888

nrrheum.2009.175

P304

543-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRRHEUM.2009.175

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26864397

http://www.w3.org/2001/XMLSchema#string

P6179

1002962565

http://www.w3.org/2001/XMLSchema#string

P698

19798028

http://www.w3.org/2001/XMLSchema#string

P932

2797318

http://www.w3.org/2001/XMLSchema#string